<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732457</url>
  </required_header>
  <id_info>
    <org_study_id>IVPPHSCT01</org_study_id>
    <nct_id>NCT02732457</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients</brief_title>
  <acronym>HSCT-HIV</acronym>
  <official_title>Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of allogeneic hematopoietic stem cell&#xD;
      transplantations (HSCT) in HIV infected patients on the persistence of HIV and the HIV immune&#xD;
      response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To assess the impact of HSCT on the immune response to HIV by measuring HIV specific&#xD;
           antigens in peripheral blood (via immune assays such as ELISA and Western blot)&#xD;
           longitudinally.&#xD;
&#xD;
        2. To measure the decay of persisting HIV by sequencing and quantitating HIV RNA in plasma,&#xD;
           and HIV DNA and RNA in peripheral blood cells including CD4+ T cells and CD4+ T cell&#xD;
           subsets, as well as in tissue cells derived from fine needle lymph node aspirates,&#xD;
           and/or bone marrow aspirates, and/or rectal tissue.&#xD;
&#xD;
        3. To determine the presence of the CCR5 delta 32 allele in the patient prior to and&#xD;
           following HSCT which will provide information regarding the presence of this gene in the&#xD;
           donor cells.&#xD;
&#xD;
        4. To correlate these findings to the clinical outcome of the individuals enrolled in this&#xD;
           study based on their clinical standard of care assessments following HSCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    5 participants recruited in 7 years (no recruitment since 2015). Due to rare patient population&#xD;
    and due to ongoing COVID-19 demands on healthcare systems, it was decided by the Protocol&#xD;
    Steering Committee to terminate this study.&#xD;
  </why_stopped>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in HIV-1 DNA levels in CD4+ T cells measured by real-time PCR</measure>
    <time_frame>3 years</time_frame>
    <description>HIV-1 DNA in CD4+ T cells will be measured by real-time PCR and reported as HIV-1 DNA copies in 10e6 CD4+ T cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in HIV-1 Antigens and Antibodies measured by ELISA and Western Blot</measure>
    <time_frame>3 years</time_frame>
    <description>HIV-1 antigens and antibodies (Ag/Ab) in peripheral blood will be measured by 4th generation chemiluminescence microparticle immunoassay (CMIA) and by Western blot (WB).</description>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>HIV-1 Infection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PBMC, BMMC, lymph-node derived cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HIV infection requiring a HSCT&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infection, requiring allogeneic, haematopoietic SCT as determined by their&#xD;
             treating Physician (Haematologist).&#xD;
&#xD;
          -  Over 18 years of age&#xD;
&#xD;
          -  Provision of written, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the opinion of the investigator that the patient is not able to provide informed&#xD;
             consent&#xD;
&#xD;
          -  Hb &lt; 9 (g/dL)&#xD;
&#xD;
          -  CD4+ T cell count &lt;100 (cells/Âµl)&#xD;
&#xD;
          -  Serious coagulation abnormalities, platelet count &lt; 50.&#xD;
&#xD;
          -  Patients currently taking medications that significantly affect the bleeding time&#xD;
             (e.g. warfarine, clexane, FXa antagonists)&#xD;
&#xD;
          -  History of allergy to local anaesthetics&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Polizzotto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincent's Hospital, Sydney</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Persistence</keyword>
  <keyword>Reservoirs</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Functional Cure</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

